GlaxoSmithKline, Neurosciences Centre of Excellence for Drug Discovery, Medicines Research Centre, Verona, Italy.
Bioorg Med Chem Lett. 2010 Aug 15;20(16):4741-4. doi: 10.1016/j.bmcl.2010.06.140. Epub 2010 Jul 1.
A novel class of small molecule NPY Y5 antagonists based around an azabicyclo[3.1.0]hexane scaffold was identified through modification of a screening hit. Structure-activity relationships and efforts undertaken to achieve a favourable pharmacokinetic profile in rat are described.
通过对筛选命中化合物的修饰,鉴定出了一类新型小分子 NPY Y5 拮抗剂,其核心骨架为氮杂双环[3.1.0]己烷。本文描述了该类化合物的构效关系以及为改善其在大鼠体内的药代动力学特征所做的努力。